Raffaella Milani

Dr. Raffaella Milani


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Corrado CampochiaroCorrado Campochiaro
Corrado Campochiaro
Emanuel Della TorreEmanuel Della Torre
Emanuel Della Torre
Marco LanzillottaMarco Lanzillotta
Marco Lanzillotta
EBEnrica Paola Bozzolo
Enrica Paola Bozzolo
EBElena Baldissera
Elena Baldissera
LDLorenzo Dagna
Lorenzo Dagna

3 October 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
Marco LanzillottaMarco Lanzillotta
Marco Lanzillotta
Emanuel Della TorreEmanuel Della Torre
Emanuel Della Torre
RMRaffaella Milani
Raffaella Milani
EBEnrica Paola Bozzolo
Enrica Paola Bozzolo
ECEmanuele Bozzalla Cassione¹
Emanuele Bozzalla Cassione¹
LDLorenzo Dagna
Lorenzo Dagna
Immunoglobulin G4-related disease (IgG4-RD) promptly responds to glucocorticoids but relapses in a considerable fraction of patients. Reliable biomarkers of flare are currently lacking because the pathophysiology of IgG4-RD remains largely elusive. In the present work, we aimed to identify perturbations of B-cell subpopulations that might predict IgG4-RD relapse. Thirty patients were treated with glucocorticoids according to international guidelines. Circulating CD19+ and CD20+ cells, naive B cells, memory B cells, plasmablasts, and plasma cells were measured by flow cytometry at baseline and every 6 months for 2 years after the initiation of corticosteroid therapy. Patients with active untreated IgG4-RD showed significantly reduced CD19+ B cells, CD20+ B cells, and naive B cells compared with healthy subjects (p < 0.05), but significantly expanded plasmablasts and plasma cells (p < 0.01). After 6 months of corticosteroid treatment, all patients achieved clinical improvement. Naive B cells, plasmablasts, and plasma cells significantly decreased compared with disease onset, whereas memory B cells significantly increased compared with baseline (p < 0.01). Increase of memory B cells was observed only in patients who relapsed within 2 years of follow-up, however (HR, 12.24; 2.99 to 50.2; p = 0.0005). In these patients, the relapse rates at 12 and 24 months were 30% and 100%, respectively. No abnormalities of other B-cell subpopulations at disease onset or after 6 months of glucocorticoid treatment were found to predict IgG4-RD relapse at 2 years. Increase of circulating memory B cells after 6 months of glucocorticoid treatment might predict IgG4-RD relapse.

7 August 2025 in Hemato
Verified
Journal Article
Open access
PDF file
Fabio BertaniFabio Bertani
Fabio Bertani
FFFrancesco Faiella
Francesco Faiella
CFClaudia Di Franco
Claudia Di Franco
RMRaffaella Milani
Raffaella Milani
AGAntonella Gualdoni
Antonella Gualdoni
ECElena Costa
Elena Costa
Monoclonal B Lymphocytosis (MBL) is considered the pre-malignant state of chronic lymphocytic leukemia (CLL) and atypical chronic lymphocytic leukemia (aCLL). Both entities are rarely found in association with other hematological tumors; still, they naturally tend to progress to more aggressive lymphomas. This manuscript reports the case of an 81-year-old Caucasian male under follow up for MBL who presented to the Emergency Department with severe anemia and thrombocytopenia. A complete diagnostic workup revealed the simultaneous presence of atypical CLL and B-acute lymphoblastic leukemia, with minimal blast presence in peripheral blood.
1